Equities

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ECILC.E:IST

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)128.80
  • Today's Change2.80 / 2.22%
  • Shares traded3.89m
  • 1 Year change+208.28%
  • Beta1.1346
Data delayed at least 15 minutes, as of Feb 16 2026 15:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS, formerly known as Eczacibasi Ilac Sanayi ve Ticaret A.S., (EIS) is a Turkey-based company active in the pharmaceutical industry through its subsidiaries, affiliates and joint ventures. Its product portfolio consists of drugs for human health, veterinary drugs and personal care products, such as body and facial creams, hair gels, deodorants and various other products. The Company is also engaged in real estate development and construction through its subsidiary, Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., formerly known as Eczacibasi Insaat ve Ticaret A.S. Its subsidiaries also include Eczacibasi Ilac Ticaret A.S. (EIT), EHP Eczacibasi Health Care Products Joint Stock Co. (EHP), and Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., among others. EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a member of Eczacibasi Group of Companies.

  • Revenue in TRY (TTM)8.89bn
  • Net income in TRY2.44bn
  • Incorporated1951
  • Employees1.10k
  • Location
    EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret ASBuyukdere Cad. Ali Kaya Sok. No:5 LeventISTANBUL 34394TurkeyTUR
  • Phone+90 2 123508000
  • Fax+90 2 123717399
  • Websitehttps://www.eis.com.tr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sihuan Pharmaceutical Holdings Group Ltd13.28bn-510.33m83.31bn2.77k--3.02--6.28-0.0098-0.00980.25750.54020.18941.493.86890,789.90-3.05-3.60-5.01-5.0566.2973.13-16.08-19.741.61-1.360.1606--2.18-7.96-301.10---20.583.60
Organon & Co275.20bn21.88bn83.91bn10.00k3.842.122.280.30491.921.9224.203.480.47911.973.98630,100.003.8111.524.8114.9455.0462.307.9520.241.202.500.906916.022.24-3.81-15.54-23.5430.71--
Ocular Therapeutix Inc2.27bn-11.62bn84.43bn325.00--2.93--37.21-1.44-1.440.27753.030.08211.991.65159,849.20-42.01-38.63-45.31-43.3187.3590.18-511.90-229.5415.32--0.0983---18.4724.45-37.43--70.20--
Tibet Rhodiola Pharmaceutical Holding Co17.20bn6.20bn85.05bn596.0013.723.79--4.953.043.048.4411.020.51881.386.524,564,666.0018.8414.9925.6119.3092.0892.1136.3123.952.89--0.197152.89-10.4517.4531.2627.47-5.1627.43
Consun Pharmaceutical Group Ltd20.68bn6.39bn85.07bn3.07k13.593.1312.494.111.331.334.315.780.56422.3512.331,169,558.0017.6014.7124.6722.8276.6275.0431.2029.563.32--0.051740.9314.5611.4216.0562.72-9.5425.83
EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr8.89bn2.44bn86.34bn1.10k35.451.5026.419.713.553.5512.9883.780.13933.475.918,173,382.003.816.404.076.8626.8733.3127.3940.471.87--0.060227.65-6.2858.48-74.1244.46151.5688.80
Ultragenyx Pharmaceutical Inc29.38bn-25.13bn86.47bn1.29k------2.94-5.84-5.846.82------------------83.8588.44-85.54-122.25---12.60----20.1319.95-1.02------
Bora Pharmaceuticals Co Ltd27.66bn6.38bn86.73bn91.0014.375.3610.773.1434.1024.33143.2891.500.45372.762.11--10.6011.3516.4818.8139.9939.4723.3619.441.07--0.554937.7235.5365.9529.9966.80-0.336374.57
Fagron NV-5.18tn-5.18tn86.88bn3.99k--3.03----------7.51----------7.72--9.52--44.06--9.751.39--0.45720.589.2011.3612.998.8410.6917.32
Perrigo Company PLC187.01bn-1.28bn87.40bn8.38k--0.456.610.4673-0.2128-0.376431.0032.310.40232.345.75511,015.60-0.2743-0.7059-0.3124-0.808235.4634.96-0.682-1.761.442.410.4505---6.062.48-3,552.27---16.2318.65
FAES Farma SA29.45bn5.45bn87.53bn756.0015.89--13.102.970.3360.3361.82--------320,062.00--13.17--15.1365.1564.6518.4920.72--155.55----9.426.6721.1711.7313.09--
Tsumura & Co54.20bn8.30bn88.89bn4.27k10.460.98857.291.64387.15387.152,524.844,095.990.3740.71062.4144,357,680.006.015.538.066.8547.6049.3916.0614.501.45--0.285631.6520.058.0094.1018.6923.0716.27
Data as of Feb 16 2026. Currency figures normalised to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's reporting currency: Turkish Lira TRY

Institutional shareholders

1.30%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 20265.08m0.74%
Dimensional Fund Advisors LPas of 30 Nov 20251.84m0.27%
BlackRock Fund Advisorsas of 06 Feb 2026401.44k0.06%
JPMorgan Investment Management, Inc.as of 05 Feb 2026363.05k0.05%
BlackRock Investment Management (UK) Ltd.as of 31 Dec 2025275.58k0.04%
Vanguard Asset Management Ltd.as of 31 Dec 2025240.59k0.04%
Charles Schwab Investment Management, Inc.as of 05 Feb 2026223.23k0.03%
Legal & General Investment Management Ltd.as of 31 Jan 2026165.88k0.02%
SSgA Funds Management, Inc.as of 05 Feb 2026160.61k0.02%
BlackRock Advisors (UK) Ltd.as of 04 Feb 2026136.89k0.02%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.